As RyR2 was demonstrated to be depleted of CaM in certain CPVTs and heart failure, EL20 may offer a selective therapeutic mechanism in CPVT and heart failure when CaM binding to RyR2 is low. The gene discussed is RYR2; the disease is catecholaminergic polymorphic ventricular tachycardia.